%0 Journal Article
%T Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma.
%A Zhang Q
%A Yin L
%A Lai Q
%A Zhao Y
%A Peng H
%J Clin Exp Med
%V 23
%N 8
%D 2023 Dec 27
%M 37759042
%F 5.057
%R 10.1007/s10238-023-01197-9
%X Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphomas with its cell origin determined to be follicular helper T-cells. AITL is characterized by a prominent tumor microenvironment involving dysregulation of immune cells, signaling pathways, and extracellular matrix. Significant progress has been made in the molecular pathophysiology of AITL, including genetic mutations, immune metabolism, hematopoietic-derived microenvironment, and non-hematopoietic microenvironment cells. Early diagnosis, detection of severe complications, and timely effective treatment are crucial for managing AITL. Treatment typically involves various combination chemotherapies, but the prognosis is often poor, and relapsed and refractory AITL remains challenging, necessitating improved treatment strategies. Therefore, this article provides an overview of the pathogenesis and latest advances in the treatment of AITL, with a focus on potential therapeutic targets, novel treatment strategies, and emerging immunotherapeutic approaches.